68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks

Summary

Patients with primary prostate cancer (low, intermediate or high metastatic risk) for whom radical prostatectomy is indicated, will be invited to participate to the present study. Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.

Timeline

Start

2018-04-25

Primary completion

2019-12-19

Completion

2019-12-19

Publications

• Results Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, Bladou F, Benard A, Hindie E, Gallerande HC, Morgat C. Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study. J Nucl Med. 2023 Mar;64(3):379-385. doi: 10.2967/jnumed.122.263889. Epub 2022 Sep 2.
• Results Schollhammer R, Quintyn Ranty ML, de Clermont Gallerande H, Cavelier F, Valverde IE, Vimont D, Hindie E, Morgat C. Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R. Cancers (Basel). 2023 Apr 18;15(8):2345. doi: 10.3390/cancers15082345.

Drugs

Indications